Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: It ain't necessarily so

Journal of the National Cancer Institute

Volumn 94, Issue 14, 2002, Pages 1041-1043

  Wolff, Antonio C ^a   Abeloff, Martin D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGE; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EDITORIAL; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; METASTASIS; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK BENEFIT ANALYSIS; SAMPLE SIZE; STATISTICAL SIGNIFICANCE;

EID: 0037125422     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.14.1041     Document Type: Editorial

References (18)

1. Polychemotherapy for early breast cancer: An overview of the randomised trials
2. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial
3. Tamoxifen for early breast cancer: An overview of the randomised trials
4. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
5. Overall survival after cyclophosphamide, adriamycin, 5-FU, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor(+), node(+) breast cancer: New findings from phase III Southwest Oncology Group S8814 (INT-0100)
6. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
7. Findings from recent national surgical adjuvant breast and bowel project adjuvant studies in stage I breast cancer
8. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG-8814)
9. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients
10. Randomized 2 × 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: An update based on 10 years' follow-up
11. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients
12. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII
13. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer
14. Polychemotherapy for early breast cancer: An overview of the randomised clinical trials with quality-adjusted survival analysis
15. Meeting highlights: International consensus panel on the treatment of primary breast cancer
16. National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000
17. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden